Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway

Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway

BackgroundEmpagliflozin (EMPA) is an SGLT-2 inhibitor that can control hyperglycemia. Clinical trials have indicated its cardio-protective effects against cardiac remodeling in diabetes or non-diabetes patients. However, the underlying molecular mechanisms of EMPA's cardio-protective effects re...

Full description

Saved in:
Bibliographic Details
Main Authors: Xun Yuan (Author), Li Pan (Author), Chi Zhang (Author), Qiulian Zhu (Author), Zexin Huang (Author), Yuan Qin (Author), Guiping Zhang (Author), Zhimei Feng (Author), Caixian Yang (Author), Ning Hou (Author)
Format: Book
Published: Frontiers Media S.A., 2024-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items